Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  inotuzumab ozogamicin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-10 of 10 for your search:
Start Over
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931022, 2011-005491-41, NCT01564784
Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K3-101, B1931004, NCT00299494
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CMC-R-GEMOX, 2011-003849-18, NCT01562990
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K5-2005, B1931001, NCT00867087
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K7-2001, B1931007, NCT00868608
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931010, 3129K6-1106, NCT01363297
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K1-100, B1931002, NCT00073749
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K3-1104, B1931005, NCT00724971
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K2-1105, B1931003, NCT01055496
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: 2009-0872, NCI-2011-01699, NCT01134575
Start Over